無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

マイクロバイオーム治療薬・診断薬の世界市場の分析・予測:〜2023年

Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

発行 Kelly Scientific Publications 商品コード 696428
出版日 ページ情報 英文 165 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
マイクロバイオーム治療薬・診断薬の世界市場の分析・予測:〜2023年 Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023
出版日: 2018年09月12日 ページ情報: 英文 165 Pages
概要

世界のマイクロバイオーム治療薬・診断薬の市場は予測期間中19.03%のCAGR (年間複合成長率) で推移し、2018年の11億3000万ドルから、2023年には27億ドルを超える規模に成長すると予測されています。

当レポートでは、世界のマイクロバイオーム治療薬・診断薬の市場を調査し、マイクロバイオームの包括的概要、治療薬・診断薬のパイプライン分析、治療/診断区分・適応症・地域別の動向と市場規模の推移と予測、市場への各種影響因子および市場機会の分析、投資・契約の動向、競合環境、主要企業のプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 マイクロバイオーム:概要

  • マイクロバイオーム:概要
  • 健康・疾患とヒトマイクロバイオーム
    • 肥満
    • 腸内細菌叢代謝
    • 2型糖尿病
    • 潰瘍性大腸炎・クローン病
    • クロストリジウムディフィシル感染症
    • 乳糖不耐症
    • CNS疾患 (腸と脳の軸)
    • 虫歯
    • 再発性細菌性膣炎・尿路感染症
    • 皮膚疾患
    • 高シュウ酸尿症
    • 尿素サイクル異常症
    • セリアック病
    • 非アルコール性脂肪性肝炎 (NASH)
    • 肝性脳症
  • マイクロバイオーム治療薬のタイプ
    • プレバイオティクス
    • プロバイオティクス
    • 該治療法 (FMT:Fecal Microbiota Transplantation)
    • 低分子薬
  • マイクロバイオーム研究における発展
  • マイクロバイオームの地域的多様性

第3章 治療薬・診断薬のパイプライン分析

  • 概要
  • クロストリジウムディフィシル
    • SER-109:Seres Therapeutics
    • SER-262:Seres Therapeutics
    • RBX2660:Rebiotix
    • VE303:Vedanta Biosciences
    • IMM-529:Immuron
    • MET-2:NuBiyota
    • CP101:Finch Therapeutics
    • ABI-M101:Assembly Biosciences
    • CBM-588:Osel
    • SYN-004:Synthetic Biologics
    • SYN-006:Synthetic Biologics
  • 潰瘍性大腸炎
    • FIN-524:Finch Therapeutics
    • SER-287:Seres Therapeutics
    • ABI-M201:Assembly Biosciences
  • クローン病
    • ABI-M301:Assembly Biosciences
    • Thetanix:4D Pharma
  • 炎症性腸疾患
    • SER-301:Seres Therapeutics
    • SGM-1019:Second Genome
    • Blautix:4D Pharma
    • SG-2-0776:Second Genome
    • IBD110:Enterome/AbbVie
  • 腫瘍・免疫関連
    • SER-401:Seres Therapeutics
    • 結腸ポリープ・結腸癌検査:Metabiomics
    • 大腸癌 (CRC) 検査:Origin Sciences
  • 移植片対宿主病 (GVHD)
    • SER-155:Seres Therapeutics
  • 尿路感染症
    • LACTIN-V:Osel
  • 肝疾患
    • SGM-1019:Second Genome
  • フェニルケトン尿症
    • SYNB1020:Synlogic
    • SYNB1618:Synlogic

第4章 市場分析・予測

  • 概要
  • 用途
    • クロストリジウムディフィシル感染症
    • 炎症性腸疾患
    • 潰瘍性大腸炎
    • クローン病
    • 肝疾患
    • 免疫・腫瘍関連
    • フェニルケトン尿症
  • 競合環境
  • 市場予測
    • 概要
    • 一次調査・臨床試験・パイププランの動向・分析
    • 収益予測
    • 市場分析・予測:地域別
    • 市場分析・予測:治療/診断区分・適応症別

第5章 市場成長推進因子・動向・SWOT分析

  • 成長推進因子・動向
  • 成長抑制因子・課題
  • 市場機会

第6章 投資・契約

第7章 ベンチャーキャピタルとマイクロバイオーム

第8章 主要企業のプロファイル

  • 4D Pharma
  • Abbvie
  • Allergan
  • Assembly Biosciences
  • Bristol Myers Squibb
  • C3J Therapeutics
  • Da Volterra
  • Enterome
  • Finch Therapeutics
  • Immuron
  • Matrisys Bioscience
  • Merck
  • Osel
  • Pfizer
  • Quorum Innovations
  • Rebiotix
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • Synthetic Biologics
  • 武田薬品工業
  • Vedanta Biosciences
目次
Product Code: 2018MM

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.

  • An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
  • Global microbiome market, global breakdown, application breakdown and leading market players
  • Detailed account of the microbiome industry market by geography, indication and company profiles
  • Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
  • Insight into the challenges faced by stakeholders
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
  • Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW

Table of Contents

Chapter 1: Executive Summary

  • 1.1. Synopsis
  • 1.2. Objective of Report
  • 1.3. Executive Summary
  • 1.4. Key Questions Answered
  • 1.5. Data Sources & Methodology

Chapter 2: Microbiome Overview

  • 2.1. Microbiome Overview
  • 2.2. Human Microbiome in Health and Disease
    • 2.2.1. Cancer
    • 2.2.2. Obesity
    • 2.2.3. Microbiota Metabolism
    • 2.2.3. Type 2 Diabetes Mellitus
    • 2.2.4. Ulcerative Colitis and Crohn's Disease
    • 2.2.5. Clostridium Difficile Infection
    • 2.2.6. Lactose Intolerance
    • 2.2.7. CNS Disorders (gut brain axis)
    • 2.2.8. Dental caries
    • 2.2.9. Recurrent Bacterial Vaginosis and Urinary Tract Infection
    • 2.2.10. Skin Diseases
    • 2.2.11. Hyperoxaluria
    • 2.2.12. Urea Cycle Disorder
    • 2.2.13. Celiac Disease
    • 2.2.14. Non-alcoholic Steatohepatitis (NASH)
    • 2.2.15. Hepatic Encephalopathy
  • 2.3. Types of Microbiome therapeutics
    • 2.3.1. Prebiotics
    • 2.3.2. Live BioTherapeutic Agents (Probiotics)
    • 2.3.3. Fecal Microbiota Transplantation (FMT)
    • 2.3.4. Small Molecules
  • 2.4. Advances in Microbiome Research
    • 2.4.1. MetaHIT Consortium
    • 2.4.2. Human Microbiome Project
    • 2.4.3. Functional Metagenomics
    • 2.4.4. Microbiome Metabolomics
    • 2.4.5. Identifying Microbiome Targets-Enterome EB8018 Case Study
  • 2.5. Geographical Variation of Microbiome Composition

Chapter 3: Human Therapeutic and Diagnostic Pipeline Analysis

  • 3.0. Synopsis
  • 3.1. Clostridium Difficile
    • 3.1.1. SER-109 Seres Therapeutics
    • 3.1.2. SER-262 Seres Therapeutics
    • 3.1.3. RBX2660 Rebiotix
    • 3.1.4. VE303 Vedanta Biosciences
    • 3.1.5. IMM-529 Immuron
    • 3.1.6. MET-2 NuBiyota
    • 3.1.7. CP101 Finch Therapeutics
    • 3.1.8. ABI-M101 Assembly Biosciences
    • 3.1.9. CBM-588 Osel
    • 3.1.10. SYN-004 Synthetic Biologics
    • 3.1.11. SYN-006 Synthetic Biologics
  • 3.2. Ulcerative Colitis
    • 3.2.1. FIN-524 Finch Therapeutics
    • 3.2.2. SER-287 Seres Therapeutics
    • 3.2.3. ABI-M201 Assembly Biosciences
  • 3.3 Crohn's Disease
    • 3.3.1. ABI-M301 Assembly Biosciences
    • 3.3.2. Thetanix 4D Pharma
  • 3.4. Inflammatory Bowel Disease
    • 3.4.1. SER-301 Seres Therapeutics
    • 3.4.2. SGM-1019 Second Genome
    • 3.4.3. Blautix 4D Pharma
    • 3.4.4. SG-2-0776 Second Genome
    • 3.4.5. IBD110-Enterome/AbbVie
  • 3.5. Immuno-Oncology
    • 3.5.1. SER-401 Seres Therapeutics
    • 3.5.2. Colon Polyp & Colon Cancer Test - Metabiomics
    • 3.5.3. Colorectal Cancer (CRC) Test-Origin Sciences
  • 3.6. Graft Versus Host Disease
    • 3.6.1. SER-155 Seres Therapeutics
  • 3.7. Urinary Tract Infections
    • 3.7.1. LACTIN-V Osel
  • 3.8. Liver Disease
    • 3.8.1. SGM-1019 Second Genome
  • 3.9. Phenylketoneuria
    • 3.9.1. SYNB1020 Synlogic
    • 3.9.2. SYNB1618 Synlogic

Chapter 4: Market Analysis & Forecast to 2023

  • 4.0. Synopsis
  • 4.1. Market Applications
    • 4.1.1. Clostridium Difficile Infection
    • 4.1.2. Inflammatory Bowel Disease
    • 4.1.3. Ulcerative Colitis
    • 4.1.4. Crohn's Disease
    • 4.1.5. Liver Disease
    • 4.1.6. Immuno-Oncology
    • 4.1.7. Phenylketonuria
  • 4.2. Competitive Landscape
  • 4.3. Market Forecast to 2023
    • 4.3.1. Synopsis
    • 4.3.2. Primary Research, Clinical Trial and Pipeline Trends and Analysis
    • 4.3.3. Revenue Generation from Global Therapeutic and Diagnostic Microbiome Market 2018-2023
    • 4.3.4. Geographical Breakdown Analysis and Forecast to 2023
  • 4.3.5. Therapeutic and Diagnostic Submarket Breakdown By Indication

Chapter 5: Market Drivers, Trends & SWOT Analysis

  • 5.1. Market Drivers & Trends
  • 5.2. Market Threats & Challenges
  • 5.3. Market Opportunities

Chapter 6: Investment and Market Deals

  • 6.1. Public and Private Funding in the Microbiome Space
  • 6.2. Current Market Deals

Chapter 7: Venture Capital and The Microbiome

  • 7.0. Synopsis
  • 7.1. How Much Investment Has been Poured into the Microbiome Space in Recent Years?
  • 7.2. What Investment Firms are Interested in the Microbiome Space?
  • 7.3. What Companies are Receiving Funding?
  • 7.4. What Funding Cycles are Emerging in this Space?

Chapter 8: Major Players and Company Profiles

  • 8.1. 4D Pharma
  • 8.2. Abbvie
  • 8.3. Allergan
  • 8.4. Assembly Biosciences
  • 8.5. Bristol Myers Squibb
  • 8.6. C3J Therapeutics
  • 8.7. Da Volterra
  • 8.8. Enterome
  • 8.9. Finch Therapeutics
  • 8.10. Immuron
  • 8.11. Matrisys Bioscience
  • 8.12. Merck
  • 8.13. Osel
  • 8.14. Pfizer
  • 8.15. Quorum Innovations
  • 8.16. Rebiotix
  • 8.17. Second Genome
  • 8.18. Seres Therapeutics
  • 8.19. Synlogic
  • 8.20. Synthetic Biologics
  • 8.21. Takeda
  • 8.22. Vedanta Biosciences

List of Exhibits

  • Exhibit 2.1: Microbiota Associated with Cancer Development
  • Exhibit 2.2: Gut Microbiota Dysbiosis and the Development of Inflammatory Immune Responses
  • Exhibit 2.3: Microbiota Metabolites
  • Exhibit 2.4: Association of Diet and Microbiota with Development of Diabetes
  • Exhibit 2.5: Dysbiotic Microbiota and Development of the Inflammatory Response Following C. difficile Infection
  • Exhibit 2.6: Host-Microbe Interactions During the Pathogenesis of Dental Caries
  • Exhibit 2.7: Brain Dysfunction Due to Altered Microbiota in Cirrhosis
  • Exhibit 2.8: Therapeutic Intervention Strategies for Microbiome Dysbiosis
  • Exhibit 2.9: Characteristics of Prebiotics and Probiotics
  • Exhibit 2.10: Probiotic Safety, Functional and Technological Usability Requirements
  • Exhibit 2.11: Probiotics Action within the Human Gut
  • Exhibit 2.12: Clinical Trials Investigating Probiotics and Obesity
  • Exhibit 2.13: Clinical Trials on Probiotics, Type 2 Diabetes & Non-Alcoholic Fatty Liver Disease
  • Exhibit 2.14: Clinical Trials Investigating Probiotics and Irritable Bowel Syndrome
  • Exhibit 2.15: Timeline of Fecal Microbiota Transplantation
  • Exhibit 2.16: Small Molecules Derived from the Human Microbiota
  • Exhibit 2.17: Gut IBD Microbiome Analysis by the Human Microbiome Project
  • Exhibit 2.18: Prediabetes Microbiome Analysis by the Human Microbiome Project
  • Exhibit 2.19: Pregnancy and Neonate Microbiome Analysis by the Human Microbiome Project
  • Exhibit 2.20: Metagenomic Analysis of the Gut Microbiome
  • Exhibit 2.21: Microbiome Metabolomic Applications in Health and Disease
  • Exhibit 2.22: Metabolites Associated with Microbial and Host metabolism
  • Exhibit 2.23: Enterome Platform to Study Gut Microbiome in IBD
  • Exhibit 2.24: Enterome EB8018 Anti-FimH Molecule for the Treatment of IBD
  • Exhibit 2.25: Global Microbiome Diversity by Geography and Body Area
  • Exhibit 3.1: Human Therapeutics Microbiome Product Pipeline
  • Exhibit 3.2: Number of Human Therapeutic and Diagnostic Microbiome Pipeline Products, Globally
  • Exhibit 3.3: Human Microbiome Therapeutics Pipeline by Drug, Company, Development Stage and Indication
  • Exhibit 3.4: IMM-529 by Immuron Mechanism of Action
  • Exhibit 4.1: Microbiome Therapeutics in Clostridium Difficile Infection
  • Exhibit 4.2.: Microbiome Therapeutic and Diagnostic Major Player Market Share Forecast 2023
  • Exhibit 4.3: Percentage of PubMed Citations by Microbiome Disease Application
  • Exhibit 4.4: Percentage of Clinical Trials by Microbiome Disease Application
  • Exhibit 4.5: Global Therapeutic and Diagnostic Microbiome Market Revenue Forecast 2018-2023
  • Exhibit 4.6: Current Global Therapeutic and Diagnostic Market Share of Microbiome Market
  • Exhibit 4.7: Global Therapeutic Microbiome Market Revenue Forecast 2018-2023
  • Exhibit 4.8: Global Diagnostic Microbiome Market Revenue Forecast 2018-2023
  • Exhibit 4.9: Geographical Microbiome Market Analysis 2018
  • Exhibit 4.10: Geographical Microbiome Market Forecast 2023
  • Exhibit 4.11: Gastrointestinal Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.12: Metabolic Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.13: Cancer Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.14: Neurological Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.15: Autoimmune Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.16: Skin Microbiome Therapeutic Market Forecast to 2023
  • Exhibit 4.17: Gastrointestinal Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.18: Metabolic Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.19: Cancer Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.20: Neurological Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.21: Autoimmune Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 4.22: Skin Disorders Microbiome Diagnostic Market Forecast to 2023
  • Exhibit 5.1: Drivers of the Microbiome Market
  • Exhibit 5.2: Threats and Challenges of the Microbiome Market
  • Exhibit 6.1: Current Market Deals in the Microbiome Space
  • Exhibit 7.1: Total Venture Capital Invested in the Microbiome Space, 2013-2017
  • Exhibit 7.2: Venture Capital Invested in the Microbiome Space by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2013-2017
  • Exhibit 7.3: Major Investment Firms and Investment Numbers in the Microbiome Industry by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2010-2017
  • Exhibit 7.4: Major Microbiome Companies and Investment Received to 2017
  • Exhibit 7.5: Microbiome Industry Investors and Companies
  • Exhibit 7.6: Major Microbiome Companies and Investment Received to 2017
  • Exhibit 7.7: Therapeutic and Diagnostic Microbiome Investments by Funding Cycle 2010-2017
  • Exhibit 8.1: 4D Pharma Development Pipeline Product Portfolio
  • Exhibit 8.2: Assembly Biosciences Pipeline Product Pipeline
  • Exhibit 8.3: Assembly BioSciences R&D Expenditure 2015-2017
  • Exhibit 8.4: C3J Therapeutics STAMP Platform
  • Exhibit 8.5: C3J Therapeutics Product Pipeline
  • Exhibit 8.6: Da Volterra Product Pipeline Portfolio
  • Exhibit 8.7: Enterome Drug Discovery Platform
  • Exhibit 8.8: Enterome Product Pipeline
  • Exhibit 8.9: Osel Pipeline Product Portfolio by Clinical Stage
  • Exhibit 8.10: Quorum Innovations Product Pipeline Portfolio
  • Exhibit 8.11: Microbiota Restoration Therapy Application Areas
  • Exhibit 8.12: Second Genome Product Pipeline Portfolio
  • Exhibit 8.13: Seres Therapeutics Product Pipeline
  • Exhibit 8.14: Seres Therapeutics R&D Expenditure 2015-2017
  • Exhibit 8.15: Synlogic Product Pipeline Portfolio
  • Exhibit 8.16: Synthetic Biologics Product Pipeline
  • Exhibit 8.17: Synthetic Biologics R&D Expenditure 2015-2017
Back to Top